Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;6(6):699-708.
doi: 10.3978/j.issn.2078-6891.2015.081.

Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer

John C McAuliffe  1 , Motaz Qadan  1 , Michael I D'Angelica  1
Affiliations
Review

Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer

John C McAuliffe et al. J Gastrointest Oncol. 2015 Dec.

Abstract

The liver is the most common site of colorectal cancer metastasis. Fortunately, improvements have been made in the care of patients with colorectal liver metastasis (CRLM). Effective management of CRLM requires a multidisciplinary approach that is tailored to individuals in order to achieve long-term survival, and cure. Resection and systemic chemotherapy provides benefit in selected individuals. An adjunct to resection and/or systemic chemotherapy is the use of hepatic arterial infusion pump (HAIP) therapy. Many studies show HAIP provides benefit for select patients with CRLM. Added to the crucible of a multidisciplinary approach to managing CRLM is the ever growing understanding of tumor biology and genetic profiling. In this review, we discuss the outcomes of resection, systemic therapies and HAIP therapy for CRLM. We also discuss the impact of recent advances in genetic profiling and mutational analysis, namely mutation of KRAS and BRAF, for this disease.

Keywords: BRAF; Colorectal liver metastasis (CRLM); FOLFOX; KRAS; hepatic artery infusion pump (HAIP); parenchymal-sparing; resection.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Waterfall plot of response to hepatic arterial infusion pump (HAIP) in phase II trial at MSKCC (40).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. - PubMed
    1. Wanebo HJ, Semoglou C, Attiyeh F, et al. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978;135:81-5. - PubMed
    1. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80. - PubMed
    1. Ekberg H, Tranberg KG, Andersson R, et al. Major liver resection: perioperative course and management. Surgery 1986;100:1-8. - PubMed
    1. Kingham TP, Correa-Gallego C, D'Angelica MI, et al. Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy. J Am Coll Surg 2015;220:471-9. - PMC - PubMed